Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (proximal tubule cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: octreotide acetate, lanreotide acetate, veldoreotide +11 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 5723
Sealed predictions
- SSTR2 in dopamine neurons, braak+0.43 (p 0.251) → -0.21 (p 0.591)receipt 5729
Swarm cases
receipt 5729: SSTR2 in dopamine neurons, braak
- power
- full sample +0.09 (p 0.715, n 18), 95% CI -0.39 to +0.54. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.10 (p 0.683, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.11 (p 0.658, n 18). could be the mix.
- skeptic
- leave-one-out range -0.02 to +0.23, sign flips 4; without severely affected donors +0.09 (p 0.715, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SSTR2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts